Orient Technologies (NSE: ORIENTTECH) Q3 FY26 results: Why short-term margin pain may be the price of securing long-cycle government and services revenue
Read More 5 minute read Pharma Industry News Solara Active Pharma’s Ambernath site clears third consecutive USFDA audit with Zero 483 observations Solara’s Ambernath facility clears USFDA audit with zero 483s, boosting investor confidence despite financial caution. Read why institutions are watching closely. byPallavi MadhirajuMay 11, 2025